LONDON (Alliance News) - Akers Biosciences Inc said Wednesday that it has begun clinical trials in the US for its PIFA PLUSS chlamydia assay, a test for chlamydia diagnosis using a finger stick blood sample.
The study will include 200 to 250 patients in total, including normal, newly infected and actively infected subjects, and previously infected and treated subjects.
It is expects to last around three months, although this may be extended.
Following the conclusion of the study it will submit regulatory documentation in the US and EU.
Shares in Akers Biosciences were trading up 4.2% at 276.00 pence Wednesday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.